iCAD to Participate in the 14th Annual Craig-Hallum Alpha Select Conference

Rhea-AI Summary

iCAD, Inc. (NASDAQ: ICAD) Announces Participation at the 14th Annual Craig-Hallum Alpha Select Conference. The company's President and CEO, Dana Brown, and CFO, Eric Lonnqvist, will be attending the conference to host one-on-one meetings with investors and attendees. The event will take place at the Sheraton New York Times Square in New York City, offering an opportunity for investors to connect with the company's management.

NASHUA, N.H., Nov. 14, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today announced that Dana Brown, President and Chief Executive Officer and Eric Lonnqvist, Chief Financial Officer, will participate at the 14^th Annual Craig-Hallum Alpha Select Conference on Thursday, November 16^th. The conference will be held at the Sheraton New York Times Square in New York City.

Management is scheduled to host one-on-one meetings with investors and attendees during the conference. Investors interested in arranging one-on-one meetings should contact their Craig-Hallum conference representative.

About iCAD
iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, NH., iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. The ProFound Breast Health Suite is cleared by the U.S. Food & Drug Administration (FDA) and has received CE mark and Health Canada licensing. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. For more information, visit www.icadmed.com.

Forward-Looking Statements
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company’s products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI^®, the benefits of the Company’s products, and future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening in light of risks of potential exposure to Covid-19, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.

Media Inquiries:
pr@icadmed.com

Investor Inquiries:
ir@icadmed.com

FAQ

What is the 14th Annual Craig-Hallum Alpha Select Conference?

The 14th Annual Craig-Hallum Alpha Select Conference is an event where companies have the opportunity to present their business strategies and financial outlook to potential investors and attendees.

Who will be attending the conference from iCAD, Inc.?

Dana Brown, President and CEO, and Eric Lonnqvist, Chief Financial Officer, will be representing iCAD, Inc. at the conference.

Where will the conference take place?

The conference will be held at the Sheraton New York Times Square in New York City.

How can investors arrange one-on-one meetings with iCAD, Inc. management?

Investors interested in arranging one-on-one meetings should contact their Craig-Hallum conference representative.

What is the mission of iCAD, Inc.?

iCAD, Inc. is on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions.